Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ida Casorelli

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Journal of Environmental Research and Public Health|October 16, 2012
DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemiasIda Casorelli, Cecilia Bossa, Margherita Bignami
Anti-Cancer Agents in Medicinal Chemistry|May 14, 2008
Role of mismatch repair and MGMT in response to anticancer therapiesIda Casorelli, Maria Teresa Russo, Margherita Bignami
DNA Repair|May 18, 2007
Methylation damage response in hematopoietic progenitor cellsIda Casorelli, Elvira Pelosi, Mauro Biffoni, et al.
DNA Repair|April 26, 2003
Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndromeIda Casorelli, Judith Offman, Luca Mele, et al.
Oncotarget|February 2, 2015
MUTYH mediates the toxicity of combined DNA 6-thioguanine and UVA radiationFrancesca Grasso, Vitalba Ruggieri, Gabriele De Luca, et al.
Cancer Research|May 14, 2009
Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesisMaria Teresa Russo, Gabriele De Luca, Ida Casorelli, et al.
Plos One|August 14, 2010
The Mutyh base excision repair gene influences the inflammatory response in a mouse model of ulcerative colitisIda Casorelli, Tania Pannellini, Gabriele De Luca, et al.
Molecular Cancer Research : MCR|May 12, 2005
Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndromeJudith Offman, Karen Gascoigne, Fiona Bristow, et al.
Journal of Translational Medicine|May 3, 2015
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanomaCarmela Rozera, Giancarlo Antonini Cappellini, Giuseppina D'Agostino, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Environmental Research and Public Health|October 16, 2012
DNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemiasIda Casorelli, Cecilia Bossa, Margherita Bignami
Anti-Cancer Agents in Medicinal Chemistry|May 14, 2008
Role of mismatch repair and MGMT in response to anticancer therapiesIda Casorelli, Maria Teresa Russo, Margherita Bignami
DNA Repair|May 18, 2007
Methylation damage response in hematopoietic progenitor cellsIda Casorelli, Elvira Pelosi, Mauro Biffoni, et al.
DNA Repair|April 26, 2003
Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndromeIda Casorelli, Judith Offman, Luca Mele, et al.
Oncotarget|February 2, 2015
MUTYH mediates the toxicity of combined DNA 6-thioguanine and UVA radiationFrancesca Grasso, Vitalba Ruggieri, Gabriele De Luca, et al.
Cancer Research|May 14, 2009
Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesisMaria Teresa Russo, Gabriele De Luca, Ida Casorelli, et al.
Plos One|August 14, 2010
The Mutyh base excision repair gene influences the inflammatory response in a mouse model of ulcerative colitisIda Casorelli, Tania Pannellini, Gabriele De Luca, et al.
Molecular Cancer Research : MCR|May 12, 2005
Repeated sequences in CASPASE-5 and FANCD2 but not NF1 are targets for mutation in microsatellite-unstable acute leukemia/myelodysplastic syndromeJudith Offman, Karen Gascoigne, Fiona Bristow, et al.
Journal of Translational Medicine|May 3, 2015
Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanomaCarmela Rozera, Giancarlo Antonini Cappellini, Giuseppina D'Agostino, et al.
Pageof 1